cat scramble program (Hypogen Inc)
90
Structured Review
Hypogen Inc
cat scramble program
Cat Scramble Program, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/catalyst+hypogen+program/pmc07474860-146-5-12
Average 90 stars, based on 1 article reviews
Cat Scramble Program, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/catalyst+hypogen+program/pmc07474860-146-5-12
Average 90 stars, based on 1 article reviews
cat scramble program - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Pharmacophore-driven identification of N-methyl-D-receptor antagonists as potent neuroprotective agents validated using in vivo studies Article Snippet: With the help of the Article Title: Development of pharmacophore similarity-based quantitative activity hypothesis and its applicability domain: applied on a diverse data-set of HIV-1 integrase inhibitors. Article Snippet: Distinguishably, the Article Title: Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists. Article Snippet: 0968-0896/$ see front matter 2010 Elsevier Ltd. A doi:10.1016/j.bmc.2010.06.047 * Corresponding author.. Tel./fax: +86 571 8882084 E-mail address: huyz@zju.edu.cn (Y. Hu).. The pharmacophore model (Hypo1) with a well prediction capacity for CysLT1 antagonists was developed using Catalyst/HypoGen program. Article Title: Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling Article Snippet: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase within the insulin receptor superfamily.. Alterations in ALK, such as rearrangements, mutations, or amplifications, have been detected in various tumours, including lymphoma, neuroblastoma, and nonsmall cell lung cancer.. In this study, we outline a computational workflow designed to uncover new inhibitors of ALK. Article Title: Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening. Article Snippet: J Mol Recognit 2016; e2604 DOI 10.1002/jmr.2604 Abstract Inhibitor kappa‐B kinase‐beta (IKK‐β) controls the activation of nuclear transcription factor kappa‐B and has been linked to inflammation and cancer.. Therefore, inhibitors of this kinase should have potent anti‐inflammatory and anticancer properties.. Accordingly, we explored the pharmacophoric space of 218 IKK‐β inhibitors to identify high‐quality binding models. Activity Assay:Article Title: Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl-1-(3-pyridyl)-1 H -1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors Article Snippet: .. The Binding Assay:Article Title: Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl-1-(3-pyridyl)-1 H -1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors Article Snippet: .. The |